Vimovo is approved for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers
TcLand Expression SA, of Nantes, France, entered a collaborative research agreement in rheumatoid arthritis with the Hospices Civils de Lyon hospital group, of Lyon, France
Kiata is being developed to treat AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis
Antares Pharma Inc., of Ewing, N.J., and Uman Pharma, of Montreal, Quebec, said they formed a strategic alliance to develop and commercialize Antares' Vibex MTX, a pressure-assisted injection device containing methotrexate under investigation to treat rheumatoid arthritis and related autoimmune conditions
Genentech Inc., of South San Francisco, a member of the Roche Group, submitted a supplemental biologics license application for Actemra (tocilizumab) for the prevention of structural joint damage (as assessed by radiograph) and improvement in physical function in adults with moderately to severely active rheumatoid arthritis
The decision was based on a growing body of preclinical evidence showing that inhibition of HDAC-6 can lead to increased expression of the FOXP3 transcription factor, which plays a role in the development and immunosuppressive function of regulatory T cells in the context of chronic diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, lupus and organ transplant rejection...MorphoSys AG, of Martinsried, Germany, and Galapagos NV, of Munich, Germany, expanded their antibody alliance
BioWorld International | Wednesday, February 24, 2010
Cel-Sci Corp., of Vienna, Va., said its CEL-2000 vaccine demonstrated that it was able to block the progression of rheumatoid arthritis in a mouse model
The decision was based on a growing body of preclinical evidence showing that inhibition of HDAC-6 can lead to increased expression of the FOXP3 transcription factor, which plays a role in the development and immunosuppressive function of regulatory T cells in the context of chronic diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, lupus and organ transplant rejection...MorphoSys AG, of Martinsried, Germany, and Galapagos NV, of Munich, Germany, expanded their antibody alliance
The funds will be used to continue development of XToll, currently in Phase II trials for rheumatoid arthritis, psoriasis and multiple sclerosis...The CD40 ligand is a key protein involved in many inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease
BioWorld International | Wednesday, February 10, 2010
Femta Pharmaceuticals Inc., of San Diego, entered a manufacturing services agreement with Lonza Group Ltd., of Basel, Switzerland, to facilitate the development and cGMP manufacturing of FM101, a high-affinity monoclonal antibody in late preclinical development for rheumatoid arthritis
Neovacs SA, of Paris, announced the start of a Phase IIa study of its TNF-Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNF alpha monoclonal antibody and who test positive for antidrug antibodies
BioWorld International | Wednesday, December 9, 2009
Active Biotech AB, of Lund, Sweden, and partner MediGene AG, of Martinsried, Germany, said the UK's Medicines and Healthcare products Regulatory Agency agreed to a continuation of RhuDex's clinical development in rheumatoid arthritis after in vitro studies did not suggest any negative effects of the drug...UCB SA, of Brussels, Belgium, said the European Commission approved Cimzia (certolizumab pegol) in combination with methotrexate for adult patients with moderate to severe rheumatoid arthritis
Immunization with a LEAPS-immunogen for herpes simplex virus activates a protective T-cell immune response against the virus in mice while a LEAPS-immunogen for treatment of rheumatoid arthritis (CEL-2000) reduces the production of the pro-inflammatory cytokines to block the progression of disease in mouse models of rheumatoid arthritis, the company said
Genentech Inc., of South San Francisco, a wholly owned member of the Roche Group, reported a third case of progressive multifocal leukoencephalopathy (PML) associated with Rituxan (rituximab) use in rheumatoid arthritis
and Biogen Idec Inc.'s European Patent 1176981, generally directed to the use of an anti-CD20 antibody for the treatment of rheumatoid arthritis